EX-2.1
from 8-K
84 pages
Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) Would Likely Cause Competitive Harm to the Company, if Publicly Disclosed. Double Asterisks Denote Omissions. Asset Purchase Agreement by and Between PTC Therapeutics, Inc. as Buyer and Bioelectron Technology Corporation, as Seller Dated as of October 1, 2019 This Document Is Not Intended to Create Nor Will It Be Deemed to Create a Legally Binding or Enforceable Offer, Acceptance of an Offer or Agreement of Any Type or Nature, Unless and Until Agreed to and Executed by All Parties
12/34/56
EX-2.1
from 8-K
249 pages
Confidential Materials Omitted and Filed Separately With the Securities and Exchange Commission. Double Asterisks Denote Omissions. Agreement and Plan of Merger by and Among PTC Therapeutics, Inc., Agility Merger Sub, Inc., Agilis Biotherapeutics, Inc., And, Solely in Its Capacity as Company Equityholder Representative, Shareholder Representative Services LLC Dated as of July 19, 2018
12/34/56